Hutchmed (China) (HCM) said Friday that China's National Medical Products Administration granted conditional approval for the new drug application for Tazverik as a treatment for adult patients with relapsed or refractory follicular lymphoma.
The company said results of a phase 2 trial supported the conditional approval, with Tazverik demonstrating "promising efficacy." Hutchmed said the ongoing SYMPHONY-1 study is intended to be the confirmatory trial to validate Tazverik's clinical benefits.
Hutchmed is in charge of Tazverik's development and commercialization in China, Hong Kong, Macau and Taiwan, while Epizyme is the marketing authorization holder in China, according to the statement.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。